CF
LXRX icon

Cantor Fitzgerald’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cantor Fitzgerald’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,522
Closed -$25.3K – 302
2023
Q4 		$25.3K Buy
+16,522
New +$19.6K 0.01% 183

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Cantor Fitzgerald's LXRX Position: Q1 2024 in Review

Cantor Fitzgerald sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2024, closing a stake of 16,522 shares — an estimated $25.3K sold.

Cantor Fitzgerald first reported a position in LXRX in Q4 2023 and held it in 1 quarter. The position peaked at $25.3K in Q4 2023. 119 funds tracked by Wall St. Rank hold LXRX as of Q1 2024.

  • Cantor Fitzgerald reported no remaining Lexicon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 16,522 Lexicon Pharmaceuticals shares in Q1 2024, an estimated $25.3K.
  • Cantor Fitzgerald first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Cantor Fitzgerald's Lexicon Pharmaceuticals position peaked at $25.3K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2024.

Based on Cantor Fitzgerald's 13F filing for Q1 2024, filed 15 May 2024.